Clinical medicine profile
Cyproterone / Ethinylestradiol
Therapeutic agent (verify pharmacological class)
- Route
- See product SmPC
- Schedule
- POM
- ATC
- Not assigned
- PPB status
- registered
This profile needs source confirmation
Some sections contain general class guidance rather than medicine-specific evidence. Confirm prescribing decisions against the current SmPC and Kenya STG/EML.
Safety essentials
The information most likely to change a prescribing or dispensing decision.
Contraindications
- [Cyproterone] Hypersensitivity to the active substance or excipients.
- Additional absolute contraindications are indication- and product-specific — consult SmPC.
Precautions
- Diabetes, hypertension, asthma, depression, risk of thrombosis, fluid retention, amenorrrhoea, oligomenorrhoea, rule out any clotting system disturbances, epilepsy, tetany, varicose veins.
Dosing matrix
Population and organ-function guidance, shown together for faster comparison.
1 OD x 21 days from day 1 of menstrual cycle. Repeated after a 7-day interval, usually for months
See label paediatric section if present; otherwise use paediatric formulary — do not extrapolate adult doses.
Review renal impairment dosing; many agents need CrCl/eGFR adjustment.
- CrCl 0–120: Confirm renal dosing in product SmPC / primary label.
Review hepatic impairment dosing; monitor LFTs if agent is hepatically cleared or hepatotoxic.
Use, effects & interactions
Indications
- Severe acne refractory to prolonged antibacterial therapy, mild to moderate idiopathic hirsutism, androgen dependent alopecia, and as oral contraceptives.
- Clinical selection for Cyproterone / Ethinylestradiol should follow culture results where relevant, Kenya STG/EML recommendations, and the current product SmPC.
- Class context: Therapeutic agent (verify pharmacological class).
- Confirm site-specific dose, duration and monitoring before prescribing.
Adverse effects
- Prolonged amenorrhoea, nausea and vomiting, thrombosis (coronary and venous) hypertension, cardiovascular accidents, weight gain, vaginal candidiasis, fluid retention, hepatic tumours, change in libido.
Drug interactions
Open multi-drug checker ↗- Fixed-dose/multi-ingredient product.
- Clinical details partially inherited from component monographs: Cyproterone / Ethinylestradiol.
- Confirm combination SmPC for exact dosing.
Mechanism & disposition
Cyproterone is a synthetic progestogen, which is an androgen inhibitor that also suppresses gonadotrophin secretion.
Read complete mechanism
Cyproterone is a synthetic progestogen, which is an androgen inhibitor that also suppresses gonadotrophin secretion. Mechanism is agent-specific. At receptor, enzyme, ion channel, transporter or microbial target level, the drug alters a physiological or pathological pathway to produce its therapeutic effect. Confirm precise molecular mechanism in current SmPC / pharmacology reference for this INN before high-stakes decisions.
Product-specific
Product-specific
See product SmPC
are product-specific. Consider food effects, protein binding, hepatic CYP/UGT
when adjusting for organ impairment, age and drug interactions. Verify parameters in the current SmPC.
Pregnancy, lactation & diet
Use only if potential benefit justifies potential risk; prefer agents with better reproductive data when alternatives exist.
Assess infant risk vs benefit of maternal therapy; prefer agents with lactation data.
Brands & loaded prices
| Brand | Manufacturer | Pack | Observed price |
|---|---|---|---|
| No reviewed brand listings are linked yet. | |||
Sources & review state
Decision support only. Confirm patient-specific decisions against the current product SmPC, Kenya STG/EML, and professional judgement.